Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 7Terminated 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Lymphoid 2

Conditions

Breast Neoplasms 433Carcinoma, Non-Small-Cell Lung 372Neoplasms 326Prostatic Neoplasms 244Leukemia, Myeloid, Acute 231Multiple Myeloma 229Neoplasm Metastasis 215Melanoma 202Lung Neoplasms 178Leukemia 172Lymphoma 170Colorectal Neoplasms 157Pancreatic Neoplasms 151Lymphoma, Non-Hodgkin 150Recurrence 149Ovarian Neoplasms 146Leukemia, Lymphocytic, Chronic, B-Cell 134Precursor Cell Lymphoblastic Leukemia-Lymphoma 131Myelodysplastic Syndromes 121Carcinoma, Renal Cell 121Lymphoma, Large B-Cell, Diffuse 111Lymphoma, Follicular 108Brain Neoplasms 101Squamous Cell Carcinoma of Head and Neck 96Head and Neck Neoplasms 96Glioblastoma 92Urinary Bladder Neoplasms 88Carcinoma, Hepatocellular 80Hodgkin Disease 73Colonic Neoplasms 73

Interventions

obatoclax 1ibrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Has results × Mastocytosis, Systemic × Clear all
NCT03214666 2022-11-10

GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies

GT Biopharma, Inc.

Phase 1/2 Terminated
12 enrolled 20 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

NCT02415608 2018-09-20

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Stanford University

Phase 2 Terminated
4 enrolled 14 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT00918931 2011-11-04

Obatoclax for Systemic Mastocytosis

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 2 charts
MyeloidOther hematologic neoplasm

Leukemia, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡